Related Experiment Video
Updated: Jan 13, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?
Caterina Alati1, Martina Pitea1, Matteo Molica2
1Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.
Relapsed and refractory acute myeloid leukemia (AML) presents significant treatment challenges due to the tumor microenvironment and lack of specific targets. Current CAR-T cell therapies face hurdles in effectively treating this aggressive leukemia.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Acute myeloid leukemia (AML) is an aggressive blood cancer with high relapse rates.
- Relapsed and refractory (R/R) AML has poor prognosis and limited survival despite treatment advances.
- Effective immunotherapies for R/R AML are lacking, complicating patient management.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy

